Who is sponsoring NCT03420430?

NCT03420430 is sponsored by Genelux Corporation.

What drugs are being tested in NCT03420430?

Interventions in NCT03420430: GL-ONC1.

What condition does NCT03420430 study?

NCT03420430 studies Advanced Stage Cancer (Solid Tumor Disease for 4 Patients), Acute Myeloid Leukemia (6 Patients).

Is NCT03420430 still recruiting?

NCT03420430 is currently no longer available. Last updated 25 September 2024.

Last reviewed 2024-09-25 · How we verify

NCT03420430

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

NO LONGER AVAILABLE Last updated 25 September 2024

What this trial tests

trial testing GL-ONC1 in Advanced Stage Cancer (Solid Tumor Disease for 4 Patients). No longer available.

Quick facts

Lead sponsor	Genelux Corporation
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS
Sites	1 location across United States

Drugs / interventions tested

GL-ONC1 — full drug profile →

Conditions studied

Advanced Stage Cancer (Solid Tumor Disease for 4 Patients) — all drugs for Advanced Stage Cancer (Solid Tumor Disease for 4 Patients) →
Acute Myeloid Leukemia (6 Patients) — all drugs for Acute Myeloid Leukemia (6 Patients) →

Sponsor

Genelux Corporation — full company profile →

Who can join

21 and older, any sex, with Advanced Stage Cancer (Solid Tumor Disease for 4 Patients) or Acute Myeloid Leukemia (6 Patients). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical trial. Expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of care options for treatment. Potential patients will be evaluated individually depending on GL-ONC1 product supply.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances of oncolytic virus in cancer therapy.
Mondal M, Guo J, He P, Zhou D. · · 2020 · cited 154× · PMID 32078405 · DOI 10.1080/21645515.2020.1723363
Vaccinia Virus-A Swiss Army Knife Against Cancer.
Stawowczyk M, Ye Y, Chen NG. · · 2025 · PMID 40723208 · DOI 10.3390/cancers17142324

Verify or expand the search:

Other trials of GL-ONC1

Trials testing the same drug.

NCT02714374 — GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03420430 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genelux Corporation
Last refreshed: 25 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03420430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing